Efficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS

Efficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS

The search for new therapeutic options for the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. The article presents the results of the double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on the efficacy and safety of divozilimab (BCD-132...

Full description

Saved in:
Bibliographic Details
Main Authors: L. P. Ananyeva, M. N. Starovoytova, I. Z. Gaydukova, G. V. Lukina, E. V. Zonova, L. V. Eliseeva, G. F. Fatkhullina, D. I. Abdulganieva, D. G. Krechikova, T. V. Kropotina, O. B. Nesmeyanova, I. B. Vinogradova, E. S. Zhugrova, L. V. Ivanova, N. E. Nikulenkova, O. R. Ziganshin, T. V. Plaksina, M. V. Zlobin, Yu. Yu. Grabovetskaya, N. F. Soroka, O. B. Ershova, T. V. Povarova, O. N. Anoshenkova, A. A. Lutsky, A. V. Zinkina-Orikhan, Yu. N. Linkova, E. A. Fokina, A. A. Porozova, A. V. Eremeeva
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2025-02-01
Series:Современная ревматология
Subjects:
divozilimab
systemic sclerosis
systemic scleroderma
Online Access:https://mrj.ima-press.net/mrj/article/view/1700
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The search for new therapeutic options for the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. The article presents the results of the double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on the efficacy and safety of divozilimab (BCD-132) in the treatment of SSc.Objective: to investigate the efficacy and safety of divozilimab in patients with SSc compared to placebo.Material and methods. After enrolment in the study, patients received divozilimab or placebo for 48 weeks, after which they were switched to an open-label divozilimab therapy until week 96.Results and discussion. Divozilimab was superior to placebo regarding the primary endpoint change in mRSS at week 48 compared to baseline, and the therapy had a positive effect on respiratory function parameters. Divozilimab treatment was well tolerated.Conclusion. Thus, divosilimab may represent a new therapeutic option for patients with SSc.
ISSN:1996-7012
2310-158X

Similar Items